Member Info for KingHomerJ

You probably also need to google valuations on medical devices, Apps, tools of similar ilk

GL in your research

If I make a device to go in a plane I make a device

This is fun.

VAL were going to go bust until share holders ousted the BOD - aka George Morris.

Prostate cancer dosing application is a medical device

Really really really?

Think you need to do alittle more homework and not Manipulate peoples opinions based on information
That’s clearly incorrect and you know it. (Read more)

It’s easy to say MC is less than an all time high - let’s pick Amazon, Google, or anything in fact yeah !!!

£20 millions where’s that from ? The purchase price of a company before they rolled the product out to 1000’s of medical centres and hospitals globally including Portugals health service - yeah nice one (laughing emoji)

No clear cut product haaa ok then do you have a medical background on the time it takes for medical devices to come to market . Emoji you pick one pretty sure the ICR and CRUK are supportive Ah well your opinion is key.

You haven’t mentioned the VAL payment of £6million on completion of there deal. Why not? Or Bicycle or Merck or Astellas or Tabula or Cellcentric or Lilly ???

Guess you would rather sit on and oil company which is chucking millions a day at nothing or maybe something???

Good luck

Changed the subject ?

See previous post reference commercial revenue generating deal which can be utilised globaly.

Growth Stock...

Not a straight answer ok. I just believe people should do research without being spoon fed.

Anyway for your benefit,

Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announces today it has entered into a partnership with Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalized medicine solutions. Through this initiative, Physiomics’ personalized docetaxel model will be integrated into TRHC’s market-leading precision dosing solution, DoseMeRx®. Both parties expect positive feedback from this initial trial with the next step being a commercial agreement.

DosemeRX as per RNS

The prostate cancer dosing application that is currently in trials to over 70 patients.

These things take years to develop- this is the answer to your question as this tech will save millions and is on the verge of signing revenue generating deal will will be realised on a monthly basis

Personally I’d expect some news pre interims IMO

History would say so…

Some news surely needs to be due and BIG as this is slowing bleeding to death

Email JM he will respond.

what email you trying?

Has anyone emails Suzi?

The fact you have held for x amount of time and sold literally just below the news flow and updates.

Absolutely screams someone who have very little understand if the business or the industry which it is in.

Not enough research or dialog with the company I guess.

Therefore I was merely stating good as laziness shouldn’t be rewarded.

GL anyway

Good.

2p. Roughly 75million MC haaaaaaaaaaa ouch

Glen this is very very very different to Deep matter.

Deep matter made zero revenue on its products - cash burn was extremely high - huge loss making - Richard Griffiths held massive % was sold down over years (oh and now owns about 28%)

PYC is in a completely different situation and field - so please before you make remarks please understand the businesses

Just a reminder with the VAL deal confirmation in Q1 and DoseMerx also.

Rerate on the cards here…

As a reminder,

Physiomics will receive a fee (capped at £6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection. Eligibility for part of this fee will be conditional on completion of an agreed programme of work by Physiomics that builds on the work already carried out under the 2011 agreement. This programme of work will start on 15 February 2021 and is required to be completed by 15 November 2021. In recognition of the collaborative nature of this new agreement, Physiomics will also be offered a seat on the ValiRx scientific advisory board.

Absolute bunch of crooks these lot, GLOWING aim the dark was mentioned previously and if anyway is old enough to remember that car crash they would have learn there lesson.

Look how many placing these guys have done - for what - it’s a lifestyle company, seem to remember its the same BOD as Global Petroleum- God help them.

They only people who win on dogs like these are

BOD and the places that pump the hell outta to flip there stock to the fools that will buy this rubbish